A recent investigation from The Guardian (Sept. 17, 2026) is a sobering reminder of how research funding decisions ripple far beyond a grant number on a spreadsheet.
What happened: A federally funded study examining Alzheimer’s disease risk among roughly 600 older adults in two historically redlined, majority-Black Pittsburgh neighborhoods had its NIH grant abruptly canceled this past August. Led by Andrea Rosso, an associate professor of epidemiology at the University of Pittsburgh, and co-researcher Tamara Dubowitz, the study explored how the built and social environment of a neighborhood can shape brain health over time.
Researchers were given just 90 days to close out the study (five months ahead of schedule) with no funding left to complete the final step: adjudicating participants’ cognitive test results with a neuropsychologist and geriatric psychiatrist. That means hundreds of aging participants who completed hours of cognitive testing, and who were promised their results, may never receive them, even though the data already exists.
Why this matters beyond one study: Black Americans are about twice as likely to develop Alzheimer’s disease as white Americans yet remain dramatically underrepresented in the research meant to understand and eventually treat it. This study was one of the efforts trying to close that gap. Its cancellation is not an isolated event. Over the past two years, the federal government has canceled, frozen, or otherwise disrupted more than 5,700 NIH-funded medical research grants, affecting tens of thousands of trial participants nationwide, across topics as varied as childhood hearing loss and pain management in childbirth.
The University of Pittsburgh is appealing the cancellation, and researchers here are also named plaintiffs in a broader lawsuit arguing that some of these funding decisions amount to censoring research whose findings are politically disfavored, with real consequences for public health.
Why we’re sharing this: It’s tempting to see funding policy as background noise, something that happens “elsewhere,” to “other people’s” grants. It isn’t. Early diagnosis is one of the few tools we have to slow Alzheimer’s progression, and every disrupted study is a delay in someone’s diagnosis, someone’s chance to plan, someone’s trust in research honored or broken. As a training program and research community built on the promise we make to the people who participate in our studies, we don’t have the luxury of looking away when that promise is put at risk.
We’ll continue to share updates on how these funding shifts affect population neuroscience and aging research broadly. If you want to read the full reporting, it’s available at The Guardian: “Hundreds of ageing Americans may not get results of Alzheimer’s study due to Trump cuts.”
